Recombinant activated factor VII in cardiac surgery: a systematic review

Area of Science:

• Cardiovascular Surgery
• Hematology
• Pharmacology

Background:

• Postoperative hemorrhage is a frequent and serious complication following cardiac surgery.
• This complication significantly increases patient morbidity, mortality, and healthcare costs.
• Recombinant activated factor VII (rFVIIa) is a hemostatic agent gaining use in cardiac surgery.

Purpose of the Study:

• To systematically review the existing evidence on the efficacy, safety, and cost of using rFVIIa in cardiac surgery.
• To evaluate the potential of rFVIIa as a treatment for refractory postoperative hemorrhage.
• To identify gaps in current research regarding rFVIIa in this clinical context.

Main Methods:

• Systematic review of literature.
• Analysis of evidence concerning rFVIIa's efficacy, safety, and cost in postoperative cardiac surgery patients.
• Assessment of studies, including those with limitations like lack of randomized controlled trials.

Main Results:

• Evidence suggests rFVIIa may be a promising option for managing refractory postoperative hemorrhage in cardiac surgery.
• Current data indicate that rFVIIa appears to be relatively safe in this patient population.
• Definitive evidence from randomized controlled trials is currently lacking.

Conclusions:

• rFVIIa demonstrates potential utility in treating severe postoperative bleeding after cardiac surgery.
• Further high-quality research, particularly randomized controlled trials, is necessary to establish definitive clinical guidelines for rFVIIa use.
• The safety profile appears favorable, but comprehensive data on efficacy and cost-effectiveness require further investigation.